Vaxart Inc (VXRT)

$0.79

-0.01

(-1.09%)▲

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $0.78
    $0.81
    $0.79
    downward going graph

    1.13%

    Downside

    Day's Volatility :3.57%

    Upside

    2.47%

    downward going graph
  • $0.52
    $1.54
    $0.79
    downward going graph

    34.18%

    Downside

    52 Weeks Volatility :66.23%

    Upside

    48.7%

    downward going graph

Returns

PeriodVaxart IncSector (Health Care)Index (Russel 2000)
3 Months
21.34%
4.8%
0.0%
6 Months
-20.78%
8.3%
0.0%
1 Year
11.81%
17.0%
0.0%
3 Years
-88.25%
20.8%
-20.8%

Highlights

Market Capitalization
178.0M
Book Value
$0.35
Earnings Per Share (EPS)
-0.45
Wall Street Target Price
4.83
Profit Margin
0.0%
Operating Margin TTM
-253.96%
Return On Assets TTM
-39.68%
Return On Equity TTM
-91.66%
Revenue TTM
13.9M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
371.4%
Gross Profit TTM
-80.9M
EBITDA
-66.3M
Diluted Eps TTM
-0.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.47
EPS Estimate Next Year
-0.41
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Vaxart Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 511.39%

Current $0.79
Target $4.83

Company Financials

FY18Y/Y Change
Revenue
4.2M
↓ 53.27%
Net Income
-18.0M
↓ 38.75%
Net Profit Margin
-432.96%
↓ 102.62%
FY19Y/Y Change
Revenue
9.9M
↑ 137.12%
Net Income
-18.6M
↑ 3.54%
Net Profit Margin
-189.06%
↑ 243.9%
FY20Y/Y Change
Revenue
4.0M
↓ 58.97%
Net Income
-32.2M
↑ 72.81%
Net Profit Margin
-796.34%
↓ 607.28%
FY21Y/Y Change
Revenue
892.0K
↓ 77.95%
Net Income
-70.5M
↑ 118.72%
Net Profit Margin
-7.9K%
↓ 7103.88%
FY22Y/Y Change
Revenue
107.0K
↓ 88.0%
Net Income
-107.8M
↑ 52.91%
Net Profit Margin
-100.7K%
↓ 92808.19%
FY23Y/Y Change
Revenue
7.4M
↑ 6796.26%
Net Income
-82.5M
↓ 23.47%
Net Profit Margin
-1.1K%
↑ 99590.85%
Q1 FY23Q/Q Change
Revenue
675.0K
↑ 2968.18%
Net Income
-25.1M
↑ 5.11%
Net Profit Margin
-3.7K%
↑ 104993.74%
Q2 FY23Q/Q Change
Revenue
1.4M
↑ 101.19%
Net Income
-22.6M
↓ 10.3%
Net Profit Margin
-1.7K%
↑ 2063.91%
Q3 FY23Q/Q Change
Revenue
446.0K
↓ 67.16%
Net Income
-17.4M
↓ 22.84%
Net Profit Margin
-3.9K%
↓ 2240.82%
Q4 FY23Q/Q Change
Revenue
3.2M
↑ 627.58%
Net Income
-17.4M
↓ 0.14%
Net Profit Margin
-535.44%
↑ 3365.91%
Q1 FY24Q/Q Change
Revenue
2.2M
↓ 32.79%
Net Income
-24.4M
↑ 40.53%
Net Profit Margin
-1.1K%
↓ 584.09%
Q2 FY24Q/Q Change
Revenue
6.4M
↑ 193.49%
Net Income
-16.5M
↓ 32.56%
Net Profit Margin
-257.24%
↑ 862.29%
FY18Y/Y Change
Total Assets
35.2M
↓ 12.15%
Total Liabilities
24.0M
↑ 12.1%
FY19Y/Y Change
Total Assets
37.0M
↑ 5.12%
Total Liabilities
24.1M
↑ 0.38%
FY20Y/Y Change
Total Assets
152.6M
↑ 312.03%
Total Liabilities
29.2M
↑ 21.17%
FY21Y/Y Change
Total Assets
221.2M
↑ 44.95%
Total Liabilities
33.6M
↑ 15.28%
FY22Y/Y Change
Total Assets
153.8M
↓ 30.44%
Total Liabilities
43.3M
↑ 28.58%
FY23Y/Y Change
Total Assets
91.8M
↓ 40.31%
Total Liabilities
34.0M
↓ 21.33%
Q1 FY23Q/Q Change
Total Assets
129.9M
↓ 15.6%
Total Liabilities
40.1M
↓ 7.29%
Q2 FY23Q/Q Change
Total Assets
122.7M
↓ 5.54%
Total Liabilities
37.6M
↓ 6.28%
Q3 FY23Q/Q Change
Total Assets
105.6M
↓ 13.87%
Total Liabilities
34.1M
↓ 9.2%
Q4 FY23Q/Q Change
Total Assets
91.8M
↓ 13.07%
Total Liabilities
34.0M
↓ 0.28%
Q1 FY24Q/Q Change
Total Assets
88.7M
↓ 3.44%
Total Liabilities
33.0M
↓ 3.07%
Q2 FY24Q/Q Change
Total Assets
113.7M
↑ 28.28%
Total Liabilities
33.7M
↑ 2.29%
FY18Y/Y Change
Operating Cash Flow
-14.5M
↓ 51.51%
Investing Cash Flow
26.2M
↑ 723.76%
Financing Cash Flow
-1.7M
↑ 332.25%
FY19Y/Y Change
Operating Cash Flow
-13.1M
↓ 10.02%
Investing Cash Flow
-850.0K
↓ 103.24%
Financing Cash Flow
16.0M
↓ 1023.08%
FY20Y/Y Change
Operating Cash Flow
-23.8M
↑ 81.44%
Investing Cash Flow
-1.2M
↑ 43.53%
Financing Cash Flow
138.3M
↑ 766.63%
FY21Y/Y Change
Operating Cash Flow
-59.8M
↑ 151.92%
Investing Cash Flow
-49.1M
↑ 3924.34%
Financing Cash Flow
125.8M
↓ 9.04%
FY22Y/Y Change
Operating Cash Flow
-94.8M
↑ 58.41%
Investing Cash Flow
-20.4M
↓ 58.42%
Financing Cash Flow
17.5M
↓ 86.12%
Q1 FY23Q/Q Change
Operating Cash Flow
-24.5M
↓ 16.09%
Investing Cash Flow
25.5M
↑ 61.14%
Financing Cash Flow
1.4M
↓ 83.48%
Q2 FY23Q/Q Change
Operating Cash Flow
-17.5M
↓ 28.57%
Investing Cash Flow
-1.6M
↓ 106.22%
Financing Cash Flow
13.9M
↑ 878.66%

Technicals Summary

Sell

Neutral

Buy

Vaxart Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vaxart Inc
Vaxart Inc
-12.3%
-20.78%
11.81%
-88.25%
113.36%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.93%
8.12%
21.23%
85.29%
239.25%
Novo Nordisk A/s
Novo Nordisk A/s
-9.85%
-6.35%
25.79%
137.8%
353.05%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.73%
77.74%
60.24%
32.45%
248.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.6%
17.7%
29.79%
160.59%
174.92%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vaxart Inc
Vaxart Inc
NA
NA
NA
-0.47
-0.92
-0.4
NA
0.35
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.04
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.53
39.53
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.47
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vaxart Inc
Vaxart Inc
Buy
$178.0M
113.36%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
239.25%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$519.8B
353.05%
39.53
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
248.92%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.8B
174.92%
32.84
-4.74%

Insights on Vaxart Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.2% return, outperforming this stock by 48.4%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.0% return, outperforming this stock by 121.6%

Institutional Holdings

  • Sio Capital Management, LLC

    6.49%

  • Vanguard Group Inc

    4.38%

  • Millennium Management LLC

    1.75%

  • Geode Capital Management, LLC

    0.97%

  • BlackRock Inc

    0.78%

  • Alyeska Investment Group, L.P.

    0.55%

Company Information

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.

Organization
Vaxart Inc
Employees
109
CEO
Dr. Sean N. Tucker Ph.D.
Industry
Health Technology

Discover More

FAQs